Provocative Test with Propofol: Experience in Patients with Cerebral Arteriovenous Malformations Who Underwent Neuroendovascular Procedures

References

1. 1.↵
   1. Fournier D,
   2. TerBrugge KG,
   3. Willinsky R,
   4. et al

   . Endovascular treatment of intracerebral arteriovenous malformations: experience in 49 cases. J Neurosurg 1991;75:228–33

   PubMed
2. 2.↵
   1. Hurst RW,
   2. Berenstein A,
   3. Kupersmith MJ,
   4. et al

   . Deep central arteriovenous malformations of the brain: the role of endovascular treatment. J Neurosurg 1995;82:190–95

   CrossRefPubMed
3. 3.↵
   1. Mounayer C,
   2. Hammami N,
   3. Piotin M,
   4. et al

   . Nidal embolization of brain arteriovenous malformations using Onyx in 94 patients. AJNR Am J Neuroradiol 2007;28:518–23

   Abstract/FREE Full Text
4. 4.↵
   1. Valavanis A,
   2. Yaçsargil MG

   . The endovascular treatment of brain arteriovenous malformations. Adv Tech Stand Neurosurg 1998;24:131–214

   PubMed
5. 5.↵
   1. Yu SC,
   2. Chan MS,
   3. Lam JM,
   4. et al

   . Complete obliteration of intracranial arteriovenous malformation with endovascular cyanoacrylate embolization: initial success and rate of permanent cure. AJNR Am J Neuroradiol 2004;25:1139–43

   Abstract/FREE Full Text
6. 6.↵
   1. Barr JD,
   2. Mathis JM,
   3. Horton JA

   . Provocative pharmacologic testing during arterial embolization. Neurosurg Clin N Am 1994;5:403–11

   PubMed
7. 7.↵
   1. Buchtel HA,
   2. Passaro EA,
   3. Selwa LM,
   4. et al

   . Sodium methohexital (Brevital) as an anesthetic in the Wada test. Epilepsia 2002;43:1056–61

   CrossRefPubMed
8. 8.↵
   1. Kim JH,
   2. Joo EY,
   3. Han SJ,
   4. et al

   . Can pentobarbital replace amobarbital in the Wada test? Epilepsy Behav 2007;11:378–83

   CrossRefPubMed
9. 9.↵
   1. Jones-Gotman M,
   2. Sziklas V,
   3. Djordjevic J,
   4. et al

   . Etomidate speech and memory test (eSAM): a new drug and improved intracarotid procedure. Neurology 2005;65:1723–29

   Abstract/FREE Full Text
10. 10.↵
    1. Silva TM,
    2. Hernández-Fustes OJ,
    3. Bueno ML,
    4. et al

    . The Wada test with propofol in a patient with epilepsy. Arq Neuropsiquiatr 2000;58:348–50

    PubMed
11. 11.↵
    1. Takayama M,
    2. Miyamoto S,
    3. Ikeda A,
    4. et al

    . Intracarotid propofol test for speech and memory dominance in man. Neurology 2004;63:510–15

    Abstract/FREE Full Text
12. 12.↵
    1. Fitzsimmons BF,
    2. Marshall RS,
    3. Pile-Spellman J,
    4. et al

    . Neurobehavioral differences in superselective Wada testing with amobarbital versus lidocaine. AJNR Am J Neuroradiol 2003;24:1456–60

    Abstract/FREE Full Text
13. 13.↵
    1. Mikuni N,
    2. Takayama M,
    3. Satow T,
    4. et al

    . Evaluation of adverse effects in intracarotid propofol injection for Wada test. Neurology 2005;65:1813–16

    Abstract/FREE Full Text
14. 14.↵
    1. Barash PG,
    2. Cullen BF,
    3. Stoelting RK,
    4. et al

    . Handbook of Clinical Anesthesia. 6th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009:1093, 1110
15. 15.↵
    Aids to the Examination of the Peripheral Nervous System. Medical Research Council. London: Her Majesty's Stationary Office, 1976.
16. 16.↵
    1. Niimi Y,
    2. Sala F,
    3. Deletis V,
    4. et al

    . Neurophysiologic monitoring and pharmacologic provocative testing for embolization of spinal cord arteriovenous malformations. AJNR Am J Neuroradiol 2004;25:1131–38

    Abstract/FREE Full Text
17. 17.↵
    1. Grote CL,
    2. Meador K

    . Has amobarbital expired? Considering the future of the Wada. Neurology 2005;65:1692–93

    FREE Full Text
18. 18.↵
    1. Malerba G,
    2. Romano-Girard F,
    3. Cravoisy A,
    4. et al

    . Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005;31:388–92

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Kotani Y,
    2. Shimazawa M,
    3. Yoshimura S,
    4. et al

    . The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties. CNS Neurosci Ther 2008:14:95–106

    CrossRefPubMed